CN113573697A - 药物制剂、含其的系统及其制备方法、应用 - Google Patents
药物制剂、含其的系统及其制备方法、应用 Download PDFInfo
- Publication number
- CN113573697A CN113573697A CN202080021975.6A CN202080021975A CN113573697A CN 113573697 A CN113573697 A CN 113573697A CN 202080021975 A CN202080021975 A CN 202080021975A CN 113573697 A CN113573697 A CN 113573697A
- Authority
- CN
- China
- Prior art keywords
- preparation
- pain
- lidocaine
- pharmaceutical preparation
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 437
- 238000002360 preparation method Methods 0.000 title claims abstract description 266
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 302
- 229960004194 lidocaine Drugs 0.000 claims abstract description 297
- 239000010410 layer Substances 0.000 claims abstract description 267
- 239000013039 cover film Substances 0.000 claims abstract description 239
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 164
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 95
- 239000010408 film Substances 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000012790 adhesive layer Substances 0.000 claims abstract description 55
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960003150 bupivacaine Drugs 0.000 claims abstract description 37
- 230000004888 barrier function Effects 0.000 claims abstract description 30
- 229960002372 tetracaine Drugs 0.000 claims abstract description 17
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims abstract description 17
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001747 cinchocaine Drugs 0.000 claims abstract description 8
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims abstract description 5
- 229960001807 prilocaine Drugs 0.000 claims abstract description 5
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims abstract description 4
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims abstract description 4
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002250 absorbent Substances 0.000 claims abstract description 4
- 230000002745 absorbent Effects 0.000 claims abstract description 4
- 229960003831 articaine Drugs 0.000 claims abstract description 4
- 229960005274 benzocaine Drugs 0.000 claims abstract description 4
- 229960003976 etidocaine Drugs 0.000 claims abstract description 4
- 229960004288 levobupivacaine Drugs 0.000 claims abstract description 4
- 229960002409 mepivacaine Drugs 0.000 claims abstract description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004919 procaine Drugs 0.000 claims abstract description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960001549 ropivacaine Drugs 0.000 claims abstract description 4
- 229940072040 tricaine Drugs 0.000 claims abstract description 3
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 208000002193 Pain Diseases 0.000 claims description 185
- 230000036407 pain Effects 0.000 claims description 184
- 210000001519 tissue Anatomy 0.000 claims description 134
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 87
- 239000000203 mixture Substances 0.000 claims description 81
- 239000013583 drug formulation Substances 0.000 claims description 74
- 239000006174 pH buffer Substances 0.000 claims description 66
- 229920001285 xanthan gum Polymers 0.000 claims description 65
- 239000000017 hydrogel Substances 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 64
- 239000000230 xanthan gum Substances 0.000 claims description 63
- 235000010493 xanthan gum Nutrition 0.000 claims description 63
- 229940082509 xanthan gum Drugs 0.000 claims description 63
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 61
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 61
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 61
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 61
- 238000009472 formulation Methods 0.000 claims description 58
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 52
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 50
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 42
- 229920002674 hyaluronan Polymers 0.000 claims description 42
- 229960003160 hyaluronic acid Drugs 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 41
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 41
- 239000003431 cross linking reagent Substances 0.000 claims description 38
- 208000002847 Surgical Wound Diseases 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 35
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 34
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 34
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 34
- 239000003292 glue Substances 0.000 claims description 30
- 229910021538 borax Inorganic materials 0.000 claims description 27
- 229920001971 elastomer Polymers 0.000 claims description 27
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 27
- 239000000375 suspending agent Substances 0.000 claims description 26
- 239000003349 gelling agent Substances 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 23
- 206010052428 Wound Diseases 0.000 claims description 21
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 21
- 238000001179 sorption measurement Methods 0.000 claims description 20
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 20
- 239000002562 thickening agent Substances 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 17
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 17
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 17
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 15
- 208000004983 Phantom Limb Diseases 0.000 claims description 14
- 206010056238 Phantom pain Diseases 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 14
- 230000002980 postoperative effect Effects 0.000 claims description 14
- 208000007514 Herpes zoster Diseases 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000004132 cross linking Methods 0.000 claims description 13
- 229920000591 gum Polymers 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 208000006820 Arthralgia Diseases 0.000 claims description 12
- 208000008035 Back Pain Diseases 0.000 claims description 12
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000000853 adhesive Substances 0.000 claims description 12
- 230000001070 adhesive effect Effects 0.000 claims description 12
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 12
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- 201000008482 osteoarthritis Diseases 0.000 claims description 11
- 235000010413 sodium alginate Nutrition 0.000 claims description 11
- 239000000661 sodium alginate Substances 0.000 claims description 11
- 229940005550 sodium alginate Drugs 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 201000005569 Gout Diseases 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 10
- 208000005890 Neuroma Diseases 0.000 claims description 9
- 208000026137 Soft tissue injury Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 7
- 229910052796 boron Inorganic materials 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 7
- 239000004328 sodium tetraborate Substances 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 6
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 6
- 229940015043 glyoxal Drugs 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
- 239000011976 maleic acid Substances 0.000 claims description 6
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 6
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 6
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 235000019737 Animal fat Nutrition 0.000 claims description 5
- 208000028389 Nerve injury Diseases 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000008764 nerve damage Effects 0.000 claims description 5
- 235000019871 vegetable fat Nutrition 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 206010033474 Pain of skin Diseases 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
- -1 polyethylene Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 239000003522 acrylic cement Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 230000009969 flowable effect Effects 0.000 claims description 2
- 238000007731 hot pressing Methods 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920006264 polyurethane film Polymers 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000013464 silicone adhesive Substances 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 26
- 229960005015 local anesthetics Drugs 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 129
- 230000000694 effects Effects 0.000 description 64
- 239000013078 crystal Substances 0.000 description 38
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 29
- 239000002245 particle Substances 0.000 description 19
- 230000036592 analgesia Effects 0.000 description 18
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 230000003139 buffering effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 11
- 159000000000 sodium salts Chemical class 0.000 description 11
- 239000012730 sustained-release form Substances 0.000 description 11
- 238000009792 diffusion process Methods 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000012467 final product Substances 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 229940042577 exparel Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 206010053615 Thermal burn Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 3
- 229940060977 lidoderm Drugs 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229940036950 pliaglis Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 229940019097 EMLA Drugs 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000012084 abdominal surgery Methods 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000012787 coverlay film Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000005135 methemoglobinemia Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
药物制剂、含其的系统及其制备方法、应用。该药物制剂包括水和局部麻醉药;该药物制剂中的局部麻醉药包括溶解的和未溶解的局部麻醉药;药物制剂中的局部麻醉药的质量百分比为2%以上;溶解的局部麻醉药在药物制剂中的质量百分比为1%以下;局部麻醉药为利多卡因、丁卡因、布比卡因、阿替卡因、辛可卡因、地布卡因、依替卡因、左布比卡因、甲哌卡因、丙胺卡因、罗哌卡因、三甲卡因、苯佐卡因或普鲁卡因;所述药物制剂中各组分的质量百分比之和为100%。该系统包括含有网状胶层、屏障膜,和吸附层的覆盖膜。在许多镇痛应用中,该系统能够获得6、12、18、24、36,甚至48小时或更长的连续镇痛效果。
Description
PCT国内申请,说明书已公开。
Claims (20)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019102999643 | 2019-04-15 | ||
CN201910299964.3A CN111821257A (zh) | 2019-04-15 | 2019-04-15 | 药物制剂、含其的系统及其制备方法、应用 |
PCT/CN2020/084970 WO2020211787A1 (zh) | 2019-04-15 | 2020-04-15 | 药物制剂、含其的系统及其制备方法、应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113573697A true CN113573697A (zh) | 2021-10-29 |
Family
ID=72837026
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910299964.3A Withdrawn CN111821257A (zh) | 2019-04-15 | 2019-04-15 | 药物制剂、含其的系统及其制备方法、应用 |
CN202080021975.6A Pending CN113573697A (zh) | 2019-04-15 | 2020-04-15 | 药物制剂、含其的系统及其制备方法、应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910299964.3A Withdrawn CN111821257A (zh) | 2019-04-15 | 2019-04-15 | 药物制剂、含其的系统及其制备方法、应用 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN111821257A (zh) |
WO (1) | WO2020211787A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102327161A (zh) * | 2011-06-16 | 2012-01-25 | 安美得生医股份有限公司 | 创伤敷料的制备工艺 |
CN103596560A (zh) * | 2010-11-09 | 2014-02-19 | 张洁 | 薄层和液体结合的透皮给药系统 |
CN203693902U (zh) * | 2013-10-25 | 2014-07-09 | 稳健实业(深圳)有限公司 | 一种硅凝胶泡沫敷贴 |
CN104825386A (zh) * | 2015-05-25 | 2015-08-12 | 湖北汇瑞药业股份有限公司 | 一种表皮麻醉凝胶及其制备方法 |
CN105579003A (zh) * | 2013-07-10 | 2016-05-11 | 张洁 | 利用液体或半固体制剂持续经皮给药的工具及其使用方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0838225A3 (en) * | 1996-10-25 | 1999-03-24 | Hiji, Yasutake | Aqueous local anesthetic solution |
US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
US20080242731A1 (en) * | 2003-07-22 | 2008-10-02 | T&A Pharma Pty. Limited | Topical anesthesia formulation for bodily cavities |
US8741332B2 (en) * | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for dermally treating neuropathic pain |
AU2008101283A4 (en) * | 2008-02-19 | 2011-07-07 | T&A Pharma Pty Limited | Topical anaesthesia compositions |
CN101658692A (zh) * | 2008-08-27 | 2010-03-03 | 山东省生物药物研究院 | 一种结冷胶组合物及其制备方法和用途 |
WO2011126898A2 (en) * | 2010-03-30 | 2011-10-13 | Sparkmed Research, Llc | Drug releasing medical catheters, tubes, and devices |
CN102018696B (zh) * | 2010-11-22 | 2013-07-03 | 北京泰德制药股份有限公司 | 一种含有利多卡因或其药用盐的皮肤外用制剂 |
CN102198126B (zh) * | 2011-05-04 | 2012-11-28 | 刘布鸣 | 治疗口腔及牙齿疾病的涂抹剂及其涂抹器 |
DK3097907T3 (en) * | 2015-05-28 | 2018-12-10 | Abdi Ibrahim Ilac Sanayi Ve Ticaret A S | A GEL formulation comprising anesthetic and anesthetic agents |
CN105903068A (zh) * | 2016-06-02 | 2016-08-31 | 四川奎星医用高分子制品有限责任公司 | 含有镇痛药物的医用复合壳聚糖凝胶 |
-
2019
- 2019-04-15 CN CN201910299964.3A patent/CN111821257A/zh not_active Withdrawn
-
2020
- 2020-04-15 CN CN202080021975.6A patent/CN113573697A/zh active Pending
- 2020-04-15 WO PCT/CN2020/084970 patent/WO2020211787A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103596560A (zh) * | 2010-11-09 | 2014-02-19 | 张洁 | 薄层和液体结合的透皮给药系统 |
CN106109444A (zh) * | 2010-11-09 | 2016-11-16 | 张洁 | 薄层和液体结合的透皮给药系统 |
CN102327161A (zh) * | 2011-06-16 | 2012-01-25 | 安美得生医股份有限公司 | 创伤敷料的制备工艺 |
CN105579003A (zh) * | 2013-07-10 | 2016-05-11 | 张洁 | 利用液体或半固体制剂持续经皮给药的工具及其使用方法 |
CN203693902U (zh) * | 2013-10-25 | 2014-07-09 | 稳健实业(深圳)有限公司 | 一种硅凝胶泡沫敷贴 |
CN104825386A (zh) * | 2015-05-25 | 2015-08-12 | 湖北汇瑞药业股份有限公司 | 一种表皮麻醉凝胶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111821257A (zh) | 2020-10-27 |
WO2020211787A1 (zh) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1336727C (en) | Flexible, hydrophilic gel film, the process for its production and the use of it | |
US6461644B1 (en) | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods | |
ES2452517T3 (es) | Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato | |
AU779570B2 (en) | Local prevention or amelioration of pain from surgically closed wounds | |
US4725609A (en) | Method of promoting healing | |
US8535709B2 (en) | Agents for controlling biological fluids and methods of use thereof | |
US20070059350A1 (en) | Agents for controlling biological fluids and methods of use thereof | |
AU2018384069A1 (en) | Wound dressing | |
US20060029654A1 (en) | Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain | |
US20200179314A1 (en) | Lidocaine Patch and Methods of Use Thereof | |
WO2020051117A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
US20240082175A1 (en) | Cannabinoid and menthol transdermal delivery systems and methods | |
US6620852B2 (en) | Topical anesthetic | |
CN111840553A (zh) | 脂性药物制剂及其应用 | |
CN111615383A (zh) | 药物组合物、贴剂及其制备方法、镇痛方法、应用 | |
US11147775B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
CN113573697A (zh) | 药物制剂、含其的系统及其制备方法、应用 | |
WO1998039042A1 (en) | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods | |
CN212913557U (zh) | 一种将半固体制剂固定在皮肤上的系统 | |
US11229610B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
CN113616626A (zh) | 具有麻醉效果的医用敷贴及其应用 | |
WO2020211763A1 (zh) | 覆盖膜、含其的系统及其使用方法、应用 | |
WO2021177940A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
JP2926914B2 (ja) | 皮膚疾患治療用貼付剤及びその製造法 | |
JP3782551B2 (ja) | 鎮痛組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |